Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity
For children, adolescents and adults with overweight or grade 1 obesity, group programmes are offered which include content on nutrition, exercise and behaviour. However, it is a challenge to reach the respective target groups and to retain the participants in the programme for the entire duration. Based on the reviewed literature, numerous strategies for recruiting target groups and improving programme adherence were identified. In addition, an overview of existing programmes in German-speaking countries was provided.
SMA therapies: Mid-to-long-term follow-up of patients treated >=24 months with nusinersen or onasemnogene abeparvovec, and >=12 months with risdiplam (mono/combination therapy)
Since 2017, three therapies have been approved by the FDA and EMA for the treatment of SMA patients: The results show clinically relevant improvements in motor skills in SMA type 1 patients, especially in patients with early treatment initiation and >=2 SMN2 copies, as well as stabilisation of health status in SMA type 2 to 4 patients. In all studies reporting these outcomes, no significant improvements in respiratory and nutritional function were recorded regardless of SMA type and therapy used, with most studies reporting no change or an increase in the need for ventilation and nutritional support.
20 observational studies and 1 RCT were included in the synthesis, reporting on a total of 1,374 patients. 15 studies investigated nusinersen in 948 patients, one study was identified on onasmenogene abeparvovec and investigated 12 patients, and two studies investigated risdiplam in 221 patients. 193 patients received combination therapy.
We are pleased to introduce you six new Fact Sheets.
Fact Sheet No. 151 (October 2023)
Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL)
Fact Sheet No. 152 (October 2023)
Elranatamab (Elrexfio®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 153 (October 2023)
Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC)
Fact Sheet No. 154 (October 2023)
Dostarlimab (Jemperli®) with carboplatin and paclitaxel for the treatment of mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) primary advanced or recurrent endometrial cancer (EC)
Fact Sheet No. 155 (October 2023)
Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma
Image-guided spinal injections in treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques
We performed a guideline synopsis to identify indications for the use of image-guided interventions and summarise the subsequent recommendations. We also considered potential organisational or social aspects.
Ten clinical guidelines fulfilled our eligibility criteria. Seven were related to epidural injections in four indications (axial discogenic pain, disc herniation, spinal stenosis, post-surgery syndrome) and five clinical guidelines on facet joint injections in one indication (axial facet joint pain). The majority are related to the lumbar spine. Only three guidelines on epidural injections and four on facet joint injections provided recommendations on imaging modalities.The synopsis of recommendation for epidural injections is inconsistent in two clinical indications, axial discogenic pain and spinal stenosis, with con-flicting recommendations across CGs. The same is true for facet joint injections, for both nerve block and intraarticular injections. The other two clinical indications for epidural injections, disc herniation and post-surgery syndrome, included both strong and weak recommendations for using epidural injections.
We are pleased to introduce you five new Fact Sheets.
Fact Sheet No. 147 (September 2023)
Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation
Fact Sheet No. 148 (September 2023)
Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC)
Fact Sheet No. 149 (September 2023)
Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM)
Fact Sheet No. 150 (September 2023)
Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML)
Community Nursing is a new model of care in Austria to strengthen the health of the elderly population. The literature review examines the cost-effectiveness of the concept and methods for presenting it. The results are inconclusive. The use of community nursing tends not to be cost-effective in the eleven identified studies, but methodological limitations may have biased the results. The studies are also older and largely not from Europe. Further research using more recent methodological findings from research on complex interventions and evaluation of public health interventions is needed.
We are pleased to introduce you eight new Fact Sheets.
Fact Sheet No. 138 (August 2023)
Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL)
Fact Sheet No. 139 (August 2023)
Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML)
Fact Sheet No. 141 (August 2023)
Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 142 (August 2023)
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Fact Sheet No. 145 (August 2023)
Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma